Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

MiR-30c impedes glioblastoma cell proliferation and migration by targeting SOX9.

Liu S, Li X, Zhuang S.

Oncol Res. 2018 Mar 1. doi: 10.3727/096504018X15193506006164. [Epub ahead of print]

PMID:
29495977
2.

Tumor-Associated Macrophages Derived from Circulating Inflammatory Monocytes Degrade Collagen through Cellular Uptake.

Madsen DH, Jürgensen HJ, Siersbæk MS, Kuczek DE, Grey Cloud L, Liu S, Behrendt N, Grøntved L, Weigert R, Bugge TH.

Cell Rep. 2017 Dec 26;21(13):3662-3671. doi: 10.1016/j.celrep.2017.12.011.

3.

Anti-tumor activity of anthrax toxin variants that form a functional translocation pore by intermolecular complementation.

Liu S, Ma Q, Fattah R, Bugge TH, Leppla SH.

Oncotarget. 2017 May 9;8(39):65123-65131. doi: 10.18632/oncotarget.17729. eCollection 2017 Sep 12.

4.

Photoelectric Dye Used for Okayama University-Type Retinal Prosthesis Reduces the Apoptosis of Photoreceptor Cells.

Liu S, Matsuo T, Hosoya O, Uchida T.

J Ocul Pharmacol Ther. 2017 Apr;33(3):149-160. doi: 10.1089/jop.2016.0093. Epub 2017 Jan 13.

5.

Surface biomimetic modification with laminin-loaded heparin/poly-l-lysine nanoparticles for improving the biocompatibility.

Liu T, Hu Y, Tan J, Liu S, Chen J, Guo X, Pan C, Li X.

Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:929-936. doi: 10.1016/j.msec.2016.11.010. Epub 2016 Nov 4.

PMID:
27987790
6.

Anthrax Toxin Protective Antigen Variants That Selectively Utilize either the CMG2 or TEM8 Receptors for Cellular Uptake and Tumor Targeting.

Chen KH, Liu S, Leysath CE, Miller-Randolph S, Zhang Y, Fattah R, Bugge TH, Leppla SH.

J Biol Chem. 2016 Oct 14;291(42):22021-22029. Epub 2016 Aug 23.

7.

Solid tumor therapy by selectively targeting stromal endothelial cells.

Liu S, Liu J, Ma Q, Cao L, Fattah RJ, Yu Z, Bugge TH, Finkel T, Leppla SH.

Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):E4079-87. doi: 10.1073/pnas.1600982113. Epub 2016 Jun 29.

8.

Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion.

Al-Dimassi S, Salloum G, Saykali B, Khoury O, Liu S, Leppla SH, Abi-Habib R, El-Sibai M.

Int J Oncol. 2016 May;48(5):1913-20. doi: 10.3892/ijo.2016.3431. Epub 2016 Mar 9.

PMID:
26984023
9.

An anthrax toxin variant with an improved activity in tumor targeting.

Wein AN, Peters DE, Valivullah Z, Hoover BJ, Tatineni A, Ma Q, Fattah R, Bugge TH, Leppla SH, Liu S.

Sci Rep. 2015 Nov 20;5:16267. doi: 10.1038/srep16267.

10.

Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF).

Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ.

Transl Oncol. 2015 Oct;8(5):347-57. doi: 10.1016/j.tranon.2015.07.001.

11.

Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.

Martin EW, Buzza MS, Driesbaugh KH, Liu S, Fortenberry YM, Leppla SH, Antalis TM.

Oncotarget. 2015 Oct 20;6(32):33534-53. doi: 10.18632/oncotarget.5214.

12.

Anthrax Pathogenesis.

Moayeri M, Leppla SH, Vrentas C, Pomerantsev AP, Liu S.

Annu Rev Microbiol. 2015;69:185-208. doi: 10.1146/annurev-micro-091014-104523. Epub 2015 Jul 16. Review.

PMID:
26195305
13.

Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.

Hu JH, Touch P, Zhang J, Wei H, Liu S, Lund IK, Høyer-Hansen G, Dichek DA.

Cardiovasc Res. 2015 Mar 1;105(3):372-82. doi: 10.1093/cvr/cvv007. Epub 2015 Jan 23.

14.

Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.

Peters DE, Hoover B, Cloud LG, Liu S, Molinolo AA, Leppla SH, Bugge TH.

Toxicol Appl Pharmacol. 2014 Sep 1;279(2):220-9. doi: 10.1016/j.taap.2014.06.010. Epub 2014 Jun 24.

15.

Surface modification with dopamine and heparin/poly-L-lysine nanoparticles provides a favorable release behavior for the healing of vascular stent lesions.

Liu T, Zeng Z, Liu Y, Wang J, Maitz MF, Wang Y, Liu S, Chen J, Huang N.

ACS Appl Mater Interfaces. 2014 Jun 11;6(11):8729-43. doi: 10.1021/am5015309. Epub 2014 Apr 23.

PMID:
24731022
16.

Anthrax lethal and edema toxins in anthrax pathogenesis.

Liu S, Moayeri M, Leppla SH.

Trends Microbiol. 2014 Jun;22(6):317-25. doi: 10.1016/j.tim.2014.02.012. Epub 2014 Mar 27. Review.

17.

Immobilization of heparin/poly-(L)-lysine nanoparticles on dopamine-coated surface to create a heparin density gradient for selective direction of platelet and vascular cells behavior.

Liu T, Liu Y, Chen Y, Liu S, Maitz MF, Wang X, Zhang K, Wang J, Wang Y, Chen J, Huang N.

Acta Biomater. 2014 May;10(5):1940-54. doi: 10.1016/j.actbio.2013.12.013. Epub 2013 Dec 14.

PMID:
24342042
18.

Endothelialization of implanted cardiovascular biomaterial surfaces: the development from in vitro to in vivo.

Liu T, Liu S, Zhang K, Chen J, Huang N.

J Biomed Mater Res A. 2014 Oct;102(10):3754-72. doi: 10.1002/jbm.a.35025. Epub 2013 Nov 16. Review.

PMID:
24243819
19.

Key tissue targets responsible for anthrax-toxin-induced lethality.

Liu S, Zhang Y, Moayeri M, Liu J, Crown D, Fattah RJ, Wein AN, Yu ZX, Finkel T, Leppla SH.

Nature. 2013 Sep 5;501(7465):63-8. doi: 10.1038/nature12510. Epub 2013 Aug 28.

20.

Anthrax toxin-mediated delivery of the Pseudomonas exotoxin A enzymatic domain to the cytosol of tumor cells via cleavable ubiquitin fusions.

Bachran C, Morley T, Abdelazim S, Fattah RJ, Liu S, Leppla SH.

MBio. 2013 Apr 30;4(3):e00201-13. doi: 10.1128/mBio.00201-13.

Supplemental Content

Loading ...
Support Center